Abstract
Introduction In response to the limited supply of personal protective equipment during the pandemic caused by SARS-CoV-2, recent studies demonstrate that gaseous H2O2 is an effective decontaminant of N95 filtering facepiece respirators to enable reuse of these items in a clinical setting. This paper evaluates the efficacy of the Arca Aerosolized Hydrogen Peroxide Decontamination System (Arca), a novel aerosolized H2O2 decontamination system, using biologic indicator testing.
Materials and Methods The Arca produces and circulates H2O2 aerosol inside of a sealed stainless steel chamber. The Arca’s decontamination efficacy was evaluated in 8 decontamination trials with 2 H2O2 concentrations (3% and 12%) and 4 decontamination cycle durations (45, 60, 90, and 120 minutes). Efficacy was evaluated by testing: 1) the concentration in parts per million (ppm) of H2O2 produced inside the chamber and the concentration in ppm of H2O2 vented from the chamber, and 2) the decontamination of Mesa Biologic Indicator filter strips (BI) inoculated with Geobacillus Stearothermophilus. Control tests were conducted by submerging BI strips in 3mL of 3% and 12% H2O2 for 120 minutes (negative controls) and by not exposing one BI strip to H2O2 (positive control).
Results Greater than 5000 ppm of H2O2 was detected on the concentration strips inside the chamber for each of the eight decontamination trials. No vented H2O2 was detected on the external concentration strips after any decontamination trial. No growth was observed for any of the negative controls after seven days. The positive control was positive for growth.
Conclusion The Arca Aerosolized Hydrogen Peroxide Decontamination System is effective at decontaminating bacterial G. Stearothermophilus at a cycle time of 45 minutes utilizing 6mL of 3% H2O2 solution.
Competing Interest Statement
The authors of this publication are members of Abaton's Board of Directors, which could be perceived as a competing interest. However, the authors do not receive a salary or any gifts-in-kind for their service on the Board, and Abaton is a 501(c)3 non profit. The Arca device design has not, nor ever will be submitted for patent. The intention of the authors is to disseminate the design as an open source document for replication in locations where it might be of assistance. The authors further declare that they in no way financially or otherwise benefitted from the grant funding and personal donations made to Abaton.
Funding Statement
The Booz Allen Foundation Innovation Fund contributed $25,000 to Abaton, a non profit corporation for the development and testing of the Arca device, including the research published in this paper. The Booz Allen Foundation is a separate legal entity from Booz Allen Hamilton and it exists as a 501(c)3 with the mission "To be a convening force for the social sector, bringing together thought leaders and diverse perspectives to use innovation and technology advancements to help solve challenging social issues and build community resilience from the ground up". No authors directly received funding from any source, including the Innovation Fund. The Innovation Fund website can be reached at https://boozallenfoundation.org/innovationfund/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
The testing results have been published on Dryad
